Literature DB >> 14662919

Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy.

Elisa Beghetto1, Wilma Buffolano, Andrea Spadoni, Mariassunta Del Pezzo, Manlio Di Cristina, Olga Minenkova, Eskild Petersen, Franco Felici, Nicola Gargano.   

Abstract

The objective of this work was to develop an antibody-specific immunoglobulin G (IgG) avidity assay to discriminate between acute and latent phases of Toxoplasma gondii infection by using recombinant antigens. One hundred twenty-one serum samples from women who developed IgG antibodies against Toxoplasma during pregnancy were used. The IgG avidities of antibodies directed against epitopes carried by fragments of GRA3, GRA7, MIC3, and SAG1 antigens were measured by performing parallel enzyme immunoassays. The avidity index for Toxoplasma-specific antibodies against a homogeneous mixture of recombinant GRA3, GRA7, MIC3, and SAG1 antigens correlated closely with the IgG avidity of antibodies against lysed whole-cell T. gondii antigen. The avidity assay performed with the recombinant MIC3 antigen highlighted the presence of avidity low-antibodies IgG exclusively in sera collected within 2 months after primary infection. The presence of T. gondii-specific, low-avidity IgG antibodies against recombinant MIC3 antigen can be used to determine the point of infection with T. gondii within a 2-month time frame after infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662919      PMCID: PMC308957          DOI: 10.1128/JCM.41.12.5414-5418.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Avidity analysis of the human immune response to a chitin binding protein of Toxoplasma gondii.

Authors:  M Villavedra; J J Battistoni; S Rossi; H Carol; A Nieto
Journal:  Int J Parasitol       Date:  2001-08       Impact factor: 3.981

2.  Multicenter evaluation of strategies for serodiagnosis of primary infection with Toxoplasma gondii.

Authors:  A Roberts; K Hedman; V Luyasu; J Zufferey; M H Bessières; R M Blatz; E Candolfi; A Decoster; G Enders; U Gross; E Guy; M Hayde; D Ho-Yen; J Johnson; B Lécolier; A Naessens; H Pelloux; P Thulliez; E Petersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-07       Impact factor: 3.267

3.  VIDAS test for avidity of Toxoplasma-specific immunoglobulin G for confirmatory testing of pregnant women.

Authors:  Jose G Montoya; Oliver Liesenfeld; Sandra Kinney; Cynthia Press; Jack S Remington
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

4.  Congenital toxoplasmosis. A prospective study of 378 pregnancies.

Authors:  G Desmonts; J Couvreur
Journal:  N Engl J Med       Date:  1974-05-16       Impact factor: 91.245

5.  Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling.

Authors:  D Dunn; M Wallon; F Peyron; E Petersen; C Peckham; R Gilbert
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

6.  Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries.

Authors:  E Beghetto; A Pucci; O Minenkova; A Spadoni; L Bruno; W Buffolano; D Soldati; F Felici; N Gargano
Journal:  Int J Parasitol       Date:  2001-12       Impact factor: 3.981

7.  Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting.

Authors:  P T Marcolino; D A Silva; P G Leser; M E Camargo; J R Mineo
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

8.  Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory.

Authors:  O Liesenfeld; J G Montoya; S Kinney; C Press; J S Remington
Journal:  J Infect Dis       Date:  2001-03-16       Impact factor: 5.226

9.  Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year.

Authors:  W Foulon; I Villena; B Stray-Pedersen; A Decoster; M Lappalainen; J M Pinon; P A Jenum; K Hedman; A Naessens
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

10.  Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries.

Authors:  Elisa Beghetto; Andrea Spadoni; Wilma Buffolano; Mariassunta Del Pezzo; Olga Minenkova; Emiliano Pavoni; Andrea Pucci; Riccardo Cortese; Franco Felici; Nicola Gargano
Journal:  Int J Parasitol       Date:  2003-02       Impact factor: 3.981

View more
  30 in total

Review 1.  Review on the identification and role of Toxoplasma gondii antigenic epitopes.

Authors:  Yanhua Wang; Guangxiang Wang; Jianping Cai; Hong Yin
Journal:  Parasitol Res       Date:  2015-11-19       Impact factor: 2.289

2.  Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products.

Authors:  Elisa Beghetto; Andrea Spadoni; Luca Bruno; Wilma Buffolano; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index.

Authors:  Eskild Petersen; Maria Victoria Borobio; Edward Guy; Oliver Liesenfeld; Valeria Meroni; Anne Naessens; Emma Spranzi; Philippe Thulliez
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

4.  Use of immunoglobulin g avidity to determine the course of disease in visceral and post-kala-azar dermal leishmaniasis patients.

Authors:  Naresh Singh Redhu; Ayan Dey; Veena Balooni; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2006-08

5.  Usefulness of Toxoplasma gondii recombinant antigens (GRA1, GRA7 and SAG1) in an immunoglobulin G avidity test for the serodiagnosis of toxoplasmosis.

Authors:  H Pietkiewicz; E Hiszczyńska-Sawicka; J Kur; E Petersen; H V Nielsen; M Paul; M Stankiewicz; P Myjak
Journal:  Parasitol Res       Date:  2006-08-08       Impact factor: 2.289

6.  Seroreactivity to and avidity for recombinant antigens in toxoplasmosis.

Authors:  Klaus-Ingmar Pfrepper; Gisela Enders; Marion Gohl; Doris Krczal; Harald Hlobil; Doris Wassenberg; Erwin Soutschek
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

7.  A new MIC1-MAG1 recombinant chimeric antigen can be used instead of the Toxoplasma gondii lysate antigen in serodiagnosis of human toxoplasmosis.

Authors:  Lucyna Holec-Gąsior; Bartłomiej Ferra; Dorota Drapała; Dariusz Lautenbach; Józef Kur
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

8.  Identification, production and assessment of two Toxoplasma gondii recombinant proteins for use in a Toxoplasma IgG avidity assay.

Authors:  Ai Ying Teh; Atefeh Amerizadeh; Sabariah Osman; Muhammad Hafiznur Yunus; Rahmah Noordin
Journal:  Pathog Glob Health       Date:  2016-10-04       Impact factor: 2.894

9.  Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.

Authors:  V Meroni; F Genco; C Tinelli; P Lanzarini; L Bollani; M Stronati; E Petersen
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

10.  Diagnosis of parasitic diseases: old and new approaches.

Authors:  Momar Ndao
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.